PMID- 35898920
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220729
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 13
DP  - 2022
TI  - Evidence of nonsurgical treatment for polycystic liver disease.
PG  - 20406223221112563
LID - 10.1177/20406223221112563 [doi]
LID - 20406223221112563
AB  - BACKGROUND: Polycystic liver disease (PCLD) is the most common extrarenal 
      manifestation of polycystic kidney disease. There is an urgent need to assess the 
      efficacy and safety of nonsurgical modalities to relieve symptoms and decrease 
      the severity of PCLD. Herein, we aimed to evaluate the efficacy of the 
      nonsurgical treatment of PCLD and the quality of life of affected patients. 
      METHODS: PubMed, Ovid, MEDLINE, EMBASE, and the Cochrane Library were searched 
      for studies on the nonsurgical modalities, either medications or radiological 
      intervention to manage PCLD. Treatment efficacy, adverse events (AEs), and 
      patient quality of life were evaluated. RESULTS: In total, 27 studies involving 
      1037 patients were selected. After nonsurgical treatment, liver volume decreased 
      by 259 ml/m [mean change (Delta) of 6.22%] and the effect was higher in the 
      radiological intervention group [-1617 ml/m (-15.49%)] than in the medication 
      group [-151 ml/m (-3.78%)]. The AEs and serious AEs rates after overall 
      nonsurgical treatment were 0.50 [95% confidence interval (CI): 0.33-0.67] and 
      0.04 (95% CI: 0.01-0.07), respectively. The results of the SF-36 questionnaire 
      showed that PCLD treatment improved physical function [physical component summary 
      score of 4.18 (95% CI: 1.54-6.83)] but did not significantly improve mental 
      function [mental component summary score of 0.91 (95% CI: -1.20 to 3.03)]. 
      CONCLUSION: Nonsurgical treatment was effective and safe for PCLD, but did not 
      improve the quality of life in terms of mental health. Radiological intervention 
      directly reduces hepatic cysts, and thus they should be considered for immediate 
      symptom relief in patients with severe symptoms, whereas medication might be 
      considered for maintenance treatment. REGISTRATION NUMBER: PROSPERO 
      (International Prospective Register of Systematic Reviews) CRD42021279597.
CI  - (c) The Author(s), 2022.
FAU - Yoo, Jeong-Ju
AU  - Yoo JJ
AD  - Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 
      College of Medicine, Soonchunhyang University, Bucheon, Republic of Korea.
FAU - Jo, Hye In
AU  - Jo HI
AD  - Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 
      College of Medicine, Soonchunhyang University, Bucheon, Republic of Korea.
FAU - Jung, Eun-Ae
AU  - Jung EA
AD  - Medical Library, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of 
      Korea.
FAU - Lee, Jae Seung
AU  - Lee JS
AD  - Department of Internal Medicine, Yonsei University College of Medicine, Seoul, 
      Republic of Korea.
FAU - Kim, Sang Gyune
AU  - Kim SG
AD  - Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 
      College of Medicine, Soonchunhyang University, Bucheon, Republic of Korea.
FAU - Kim, Young Seok
AU  - Kim YS
AD  - Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, 
      College of Medicine, Soonchunhyang University, Bucheon, Republic of Korea.
FAU - Kim, Beom Kyung
AU  - Kim BK
AUID- ORCID: 0000-0002-5363-2496
AD  - Department of Internal Medicine, Yonsei University College of Medicine, 50-1 
      Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20220721
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC9310217
OTO - NOTNLM
OT  - efficacy
OT  - intervention
OT  - medication
OT  - meta-analysis
OT  - polycystic liver disease
OT  - safety
COIS- Competing interests: All authors have completed the ICMJE uniform disclosure 
      form. The authors have no conflicts of interest to declare.
EDAT- 2022/07/29 06:00
MHDA- 2022/07/29 06:01
PMCR- 2022/07/21
CRDT- 2022/07/28 02:17
PHST- 2022/02/08 00:00 [received]
PHST- 2022/06/21 00:00 [accepted]
PHST- 2022/07/28 02:17 [entrez]
PHST- 2022/07/29 06:00 [pubmed]
PHST- 2022/07/29 06:01 [medline]
PHST- 2022/07/21 00:00 [pmc-release]
AID - 10.1177_20406223221112563 [pii]
AID - 10.1177/20406223221112563 [doi]
PST - epublish
SO  - Ther Adv Chronic Dis. 2022 Jul 21;13:20406223221112563. doi: 
      10.1177/20406223221112563. eCollection 2022.